Peptides Similar to Mazdutide
Compare Mazdutide with related peptides and alternatives
📌TL;DR
- •4 similar peptides identified
- •Semaglutide: Both are once-weekly injectable peptides for weight management and diabetes. Both activate GLP-1 receptor for appetite reduction and glycemic control.
- •Tirzepatide: Both are dual-receptor agonist peptides with once-weekly dosing and C20 fatty acid conjugation for albumin binding and extended half-life.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Mazdutide (current) | - | - |
| Semaglutide | Both are once-weekly injectable peptides for weight management and diabetes. Both activate GLP-1 receptor for appetite reduction and glycemic control. | Semaglutide is a pure GLP-1 receptor agonist. Mazdutide adds glucagon receptor agonism for enhanced energy expenditure. Different parent hormones (GLP-1 vs oxyntomodulin). |
| Tirzepatide | Both are dual-receptor agonist peptides with once-weekly dosing and C20 fatty acid conjugation for albumin binding and extended half-life. | Tirzepatide targets GLP-1R + GIPR while mazdutide targets GLP-1R + GCGR. Different co-agonist partners (GIP vs glucagon) produce distinct metabolic profiles. |
| Survodutide | Both are dual GLP-1/glucagon receptor agonists derived from oxyntomodulin with nearly identical mechanism of action. | Survodutide uses a C18 fatty acid (29 amino acids), mazdutide uses C20 fatty diacid (33 amino acids). Different development focus: survodutide emphasizes MASH/liver disease, mazdutide focuses on obesity/T2D. |
| Retatrutide | Both activate glucagon receptor alongside GLP-1 receptor for enhanced metabolic effects beyond GLP-1 agonism alone. | Retatrutide is a triple agonist (GLP-1/GIP/glucagon) while mazdutide is a dual agonist (GLP-1/glucagon). Retatrutide targets three receptors simultaneously. |
SemaglutideBoth are once-weekly injectable peptides for weight management and diabetes. Both activate GLP-1 receptor for appetite reduction and glycemic control.
Differences
Semaglutide is a pure GLP-1 receptor agonist. Mazdutide adds glucagon receptor agonism for enhanced energy expenditure. Different parent hormones (GLP-1 vs oxyntomodulin).
Advantages
Semaglutide has global regulatory approval, cardiovascular outcomes data (SELECT trial), and extensive long-term safety data. Mazdutide may provide greater weight loss through dual mechanism.
Disadvantages
Semaglutide lacks glucagon-mediated energy expenditure. Mazdutide has limited long-term data and approval only in China so far.
TirzepatideBoth are dual-receptor agonist peptides with once-weekly dosing and C20 fatty acid conjugation for albumin binding and extended half-life.
Differences
Tirzepatide targets GLP-1R + GIPR while mazdutide targets GLP-1R + GCGR. Different co-agonist partners (GIP vs glucagon) produce distinct metabolic profiles.
Advantages
Tirzepatide has global approval and extensive Phase III data showing up to 22.5% weight loss. Mazdutide glucagon component may enhance energy expenditure and hepatic fat reduction.
Disadvantages
No head-to-head comparison exists. Different co-agonist partners make direct comparison complex.
SurvodutideBoth are dual GLP-1/glucagon receptor agonists derived from oxyntomodulin with nearly identical mechanism of action.
Differences
Survodutide uses a C18 fatty acid (29 amino acids), mazdutide uses C20 fatty diacid (33 amino acids). Different development focus: survodutide emphasizes MASH/liver disease, mazdutide focuses on obesity/T2D.
Advantages
Survodutide has advanced MASH trial data. Mazdutide achieved regulatory approval first (China, 2025).
Disadvantages
Limited direct comparison data. Different geographic development focus.
RetatrutideBoth activate glucagon receptor alongside GLP-1 receptor for enhanced metabolic effects beyond GLP-1 agonism alone.
Differences
Retatrutide is a triple agonist (GLP-1/GIP/glucagon) while mazdutide is a dual agonist (GLP-1/glucagon). Retatrutide targets three receptors simultaneously.
Advantages
Retatrutide Phase II showed up to 24.2% weight loss. Mazdutide simpler dual mechanism may have more predictable safety profile.
Disadvantages
Neither has extensive long-term data. Triple agonism adds mechanistic complexity.
Peptides Related to Mazdutide#
Mazdutide belongs to the rapidly expanding class of incretin-based multi-receptor agonist peptides for obesity and type 2 diabetes. The therapeutic landscape has evolved from single-target GLP-1 receptor agonists to dual and triple agonists combining GLP-1 signaling with GIP and/or glucagon receptor activation. Understanding how mazdutide compares with these related compounds is essential for evaluating its position in the treatment landscape.
Mazdutide vs Semaglutide#
Semaglutide (Ozempic/Wegovy) is the most widely prescribed GLP-1 receptor agonist globally and represents the standard comparator for all newer metabolic peptides.
Mechanistic Comparison#
Semaglutide activates only the GLP-1 receptor, producing appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. Mazdutide activates both GLP-1 and glucagon receptors, adding energy expenditure enhancement and lipolysis promotion through the glucagon component. The DREAMS-3 head-to-head Phase III trial showed mazdutide may demonstrate superior glycemic control and weight loss versus semaglutide in Chinese adults with type 2 diabetes and obesity.
Efficacy Comparison#
In separate trials, semaglutide 2.4 mg achieved approximately 15-17% body weight reduction at 68 weeks (STEP program), while mazdutide 9 mg achieved up to 20.1% at 60 weeks (GLORY program). Cross-trial comparisons are limited by different populations and trial designs.
Safety and Evidence Maturity#
Semaglutide has the most comprehensive safety database of any GLP-1 agonist, including the landmark SELECT cardiovascular outcomes trial showing 20% MACE reduction. Mazdutide lacks cardiovascular outcomes data, a significant gap for clinical decision-making.
Mazdutide vs Tirzepatide#
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP receptor agonist that has achieved among the highest weight loss results of approved therapies.
Different Co-Agonist Strategies#
The key difference lies in co-agonist partners: tirzepatide combines GLP-1 with GIP agonism, while mazdutide combines GLP-1 with glucagon agonism. GIP co-agonism enhances insulin secretion and has complex effects on fat metabolism. Glucagon co-agonism enhances hepatic energy expenditure, promotes lipolysis, and may provide superior hepatic fat reduction.
Clinical Outcomes#
Tirzepatide 15 mg achieved approximately 22.5% weight loss at 72 weeks (SURMOUNT-1) with global regulatory approval. Mazdutide 9 mg achieved up to 20.1% at 60 weeks with approval in China. No head-to-head trial exists.
Mazdutide vs Survodutide#
Survodutide (BI 456906) is the closest mechanistic analog to mazdutide, both being dual GLP-1/glucagon receptor agonists derived from oxyntomodulin.
Molecular and Clinical Differences#
Survodutide is a 29-amino acid peptide with C18 fatty acid (vs mazdutide's 33 amino acids and C20 fatty diacid). Survodutide has generated particular interest for MASH treatment, with Phase II data showing significant liver fat reduction and histological improvement. Mazdutide's clinical program focuses on obesity and type 2 diabetes.
Development Status#
Mazdutide achieved regulatory approval first (China, June 2025) while survodutide remains in Phase III development. Both target the same dual receptor pathways but have distinct geographic and indication strategies.
Mazdutide vs Retatrutide#
Retatrutide (LY3437943) is a triple agonist targeting GLP-1, GIP, and glucagon receptors, representing the most pharmacologically complex compound in this class.
Triple vs Dual Agonism#
Retatrutide's Phase II trial showed remarkable weight loss of up to 24.2% at 48 weeks, the highest reported for any anti-obesity agent. The addition of GIP to GLP-1/glucagon agonism may provide additional metabolic benefits, though the incremental contribution of each pathway is difficult to separate. Mazdutide's simpler dual-agonist profile may offer clearer mechanistic interpretation and more predictable safety.
Comparison Summary#
| Feature | Mazdutide | Semaglutide | Tirzepatide | Survodutide | Retatrutide |
|---|---|---|---|---|---|
| Receptors | GLP-1R + GCGR | GLP-1R | GLP-1R + GIPR | GLP-1R + GCGR | GLP-1R + GIPR + GCGR |
| Max weight loss | ~20.1% (60w) | ~17% (68w) | ~22.5% (72w) | ~19% (46w) | ~24.2% (48w) |
| Dosing | Weekly SC | Weekly SC | Weekly SC | Weekly SC | Weekly SC |
| Approval | China (2025) | Global | Global | Phase III | Phase III |
| CV outcomes | Pending | SELECT positive | SURPASS-CVOT | Pending | Pending |
| MASH data | Limited | Limited | Phase II | Phase II positive | Phase II |
Evidence Gaps#
- No head-to-head trials between mazdutide and tirzepatide or retatrutide exist
- Cross-trial comparisons limited by different populations and designs
- Relative contributions of glucagon vs GIP co-agonism to metabolic outcomes unclear
- Long-term comparative safety data not available
- Effects on body composition (lean mass vs fat mass) across agents not well characterized
Related Reading#
Frequently Asked Questions About Mazdutide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer